Open an account

Entera Bio

ENTX · NASDAQ

$3.02+$0.08 (+2.72%)TodayMarket closed ·
Prev close $2.94

ENTX analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy5
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $9.86 (+226.5% upside)

Low
$9.09
Now
$3.02
High
$11.55

Upgrades and downgrades

The latest rating actions, newest first

ENTX analyst upgrades, downgrades and rating actions
FirmDateActionRating
GuggenheimSep 25, 2026InitiatesBuy
LifeSci CapitalSep 23, 2026InitiatesOutperform
Cantor FitzgeraldSep 22, 2026InitiatesOverweight
Leerink PartnersSep 18, 2026InitiatesOutperform
HC Wainwright & Co.Apr 27, 2026MaintainsBuy
HC Wainwright & Co.Feb 9, 2026MaintainsBuy

The case for and against

Updated Oct 18, 2026

Bull case

Entera Bio is viewed favorably because its N-Tab platform could unlock oral delivery for peptides that are normally injectable, creating multiple shots on goal through EB613, EB612, EB618, and GLP-2 despite the latter assets still being preclinical. The strongest fundamental catalyst is EB613, which already showed Phase 2 efficacy on bone mineral density and biomarkers with broadly Forteo-like safety, while FDA alignment on a single 12-month Phase 3 using BMD as the endpoint materially shortens and de-risks development. Financially, the company is framed as a deep-value, high-upside story with a fully diluted market cap of about $565M and roughly $255M in pro-forma cash after a July PIPE, while some models see ~\$1.1B in annual US sales by 2040 and ~\$2.2B recorded revenue potential.

Bear case

Entera Bio is a clinical-stage company with no near-term profitability, as management’s cash runway into 2030 still does not offset the expectation of losses until 2032 and the likelihood of additional capital raises that could dilute shareholders. The bearish case is centered on EB613, which remains in clinical development and faces meaningful risk from trial setbacks, regulatory uncertainty around the 12-month Phase 3 readout, reimbursement pressure, and the challenge of displacing entrenched osteoporosis therapies. Even with a 75% probability of success and promising early data, the stock’s valuation remains vulnerable because the program must still prove compelling efficacy, consistent exposure, and commercial adoption in a cost-sensitive market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.